SCHEMBL127303

SCHEMBL127303

CN(C)c1ccc(N)c(SS(=O)(=O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
HPGD P15428 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HSP90AA1 P07900 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NSD2 O96028 1/20 0.38
G6PD P11413 1/20 0.38
IDE P14735 1/20 0.38
ALOX15 P16050 4/20 0.35
CYP3A4 P08684 2/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CA2 P00918 3/20 0.35
KDM4E B2RXH2 3/20 0.35
CA1 P00915 1/20 0.35
HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL743427 1.00 ALDH1A1 (0.39) ALDH1A1HPGDMEN1KMT2AHSP90AA1
SCHEMBL195345 0.84 MEN1 (0.45) ALDH1A1HPGDMEN1KMT2AHSP90AA1
SCHEMBL150570 0.83 ALDH1A1 (0.58) ALDH1A1HPGDMEN1KMT2AHSP90AA1
SCHEMBL5512903 0.80 MEN1 (0.44) ALDH1A1HPGDMEN1KMT2AHSP90AA1
SCHEMBL3105615 0.80 NSD2 (0.35) ALDH1A1HPGDMEN1KMT2AL3MBTL1
SCHEMBL179662 0.79 MEN1 (0.37) ALDH1A1HPGDMEN1KMT2AHSP90AA1
Sulfuric Acid SCHEMBL7805762 0.77 KDM4E (0.50) ALDH1A1HPGDMEN1KMT2ANSD2
SCHEMBL3474313 0.77 MEN1 (0.33) ALDH1A1HPGDMEN1KMT2AHSP90AA1
SCHEMBL127207 0.74 ALDH1A1 (0.43) ALDH1A1G6PDIDEALOX15CYP3A4
SCHEMBL3477837 0.74 MEN1 (0.37) ALDH1A1HPGDMEN1KMT2AHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250205370-A1 SYNTHESIS OF TOLUIDINE BLUE O AND A KIT FOR MUCOSAL APPLICATION PANDA SWAGATIKA (IN) 2025-06-26 US claimed
WO-2023181060-A1 SYNTHESIS OF TOLUIDINE BLUE O AND A KIT FOR MUCOSAL APPLICATION PANDA SWAGATIKA (IN) 2023-09-28 WO claimed
US-7659057-B2 Stain-directed molecular analysis for cancer prognosis and diagnosis ZILA BIOTECHNOLOGY, INC. (US) 2010-02-09 US claimed
EP-1944607-A2 Toluidine blue O compounds and their manufacture, analysis and use Zila, Inc. (US) 2008-07-16 EP claimed
CN-1188173-C Vivo stain composition, process of manufacture, methods of use to identify dysplastic tissue ZILA INC (US) 2005-02-09 CN claimed
US-20020111501-A1 Process for manufacture of in vivo stain composition BURKETT DOUGLAS D (US) 2002-08-15 US claimed
US-6372904-B2 OXIDIZING N,N'-DIMETHYL-P-PHENYLENE DIAMINE IN FIRST REACTION MIXTURE, INTRODUCING SODIUM THIOSULFATE IONS TO FORM 2-AMINO-5-DIMETHYLAMINOPHENYL THIOSULFONIC ACID, OXIDING THE INTERMEDIATE WITH O-TOLUDINE TO FORM SECOND INTERMEDIATE ZILA, INC. 2002-04-16 US claimed
US-20010007904-A1 Process for manufacture of in vivo stain composition MIDCAP FUNDING V, LLC, AS ADMINISTRATIVE AGENT 2001-07-12 US claimed
US-6086852-A CONFORMATIONAL ISOMERS OF TOLUIDINE BLUE O, AND N-DEMETHYLATION DERIVATIVES; SYNTHESIS, IN WHICH A COMPLEXING AGENT IS INTRODUCED PRIOR TO THE LAST STAGE OF OXIDATION OF A THREE-STEP SYNTHESIS FROM N,N-DIMETHYL-P-PHENYLENEDIAMINE ZILA, INC. (US) 2000-07-11 US claimed
EP-0966957-A2 In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue Zila Inc. (US) 1999-12-29 EP claimed
CN-1225278-A In vivo staining composition, method for preparing the same and method for identifying dysplastic tissue ZILA INC (US) 1999-08-11 CN claimed
WO-1999025388-A1 IN VIVO STAIN COMPOSITION, PROCESS OF MANUFACTURE, AND METHODS OF USE TO IDENTIFY DYSPLASTIC TISSUE ZILA, INC. (US) 1999-05-27 WO claimed
US-4212971-A Process for preparing methylene blue AMERICAN CYANAMID COMPANY (US) 1980-07-15 US claimed
JP-11209357-A None JP disclosed
US-20250205370-A1 SYNTHESIS OF TOLUIDINE BLUE O AND A KIT FOR MUCOSAL APPLICATION PANDA SWAGATIKA (IN) 2025-06-26 US disclosed
WO-2025082959-A1 A PHENOTHIAZINE-RELATED COMPOUND CONJUGATED TO A PEPTIDE UNIVERSITY OF ULSTER (GB) 2025-04-24 WO disclosed
US-5532171-A PHENOTHIAZINE DYES FOR PHOTODYNAMIC THERAPY OF CANCER OR IMMUNOASSAY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-07-02 US disclosed
US-5344928-A Phenothiazine compounds for cancer treatment or immunoassay using chemiluminescence TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-09-06 US disclosed
EP-0510668-A2 Phenothiazine derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-10-28 EP disclosed
US-4212971-A Process for preparing methylene blue AMERICAN CYANAMID COMPANY (US) 1980-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250205370-A1 SYNTHESIS OF TOLUIDINE BLUE O AND A KIT FOR MUCOSAL APPLICATION KIT, MKI67, KDM5B ALDH1A1 177/4885HPGD 1547/4885MEN1 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.